Medvedev, Melissa M; Tumukunde, Victor; Mambule, Ivan; Tann, Cally J; Waiswa, Peter; Canter, Ruth R; Hansen, Christian H; Ekirapa-Kiracho, Elizabeth; Katumba, Kenneth; Pitt, Catherine; +7 more... Greco, Giulia; Brotherton, Helen; Elbourne, Diana; Seeley, Janet; Nyirenda, Moffat; Allen, Elizabeth; Lawn, Joy E; (2020) Operationalising kangaroo Mother care before stabilisation amongst low birth Weight Neonates in Africa (OMWaNA): protocol for a randomised controlled trial to examine mortality impact in Uganda. Trials, 21 (1). 126-. DOI: https://doi.org/10.1186/s13063-019-4044-6

Downloaded from: http://researchonline.lshtm.ac.uk/id/eprint/4656002/

DOI: https://doi.org/10.1186/s13063-019-4044-6

Usage Guidelines:

Please refer to usage guidelines at https://researchonline.lshtm.ac.uk/policies.html or alternatively contact researchonline@lshtm.ac.uk.

Available under license: http://creativecommons.org/licenses/by/2.5/
Operationalising kangaroo Mother care before stabilisation amongst low birth Weight Neonates in Africa (OMWaNA): protocol for a randomised controlled trial to examine mortality impact in Uganda

Melissa M. Medvedev 1,2,3*, Victor Tumukunde 4, Ivan Mambule 4, Cally J. Tann 1,3,4,5, Peter Waiswa 6,7, Ruth R. Canter 3, Christian H. Hansen 3,4, Elizabeth Ekirapa-Kiracho 6, Kenneth Katumba 4, Catherine Pitt 8, Giulia Greco 4,6,8, Helen Brotherton 1,3,9, Diana Elbourne 3, Janet Seeley 4,8, Moffat Nyirenda 3,4, Elizabeth Allen 3 and Joy E. Lawn 1,3

Abstract

Background: There are 2.5 million neonatal deaths each year; the majority occur within 48 h of birth, before stabilisation. Evidence from 11 trials shows that kangaroo mother care (KMC) significantly reduces mortality in stabilised neonates; however, data on its effect among neonates before stabilisation are lacking. The OMWaNA trial aims to determine the effect of initiating KMC before stabilisation on mortality within seven days relative to standard care. Secondary objectives include exploring pathways for the intervention’s effects and assessing incremental costs and cost-effectiveness between arms.

Methods: We will conduct a four-centre, open-label, individually randomised, superiority trial in Uganda with two parallel groups: an intervention arm allocated to receive KMC and a control arm receiving standard care. We will enrol 2188 neonates (1094 per arm) for whom the indication for KMC is ‘uncertain’, defined as receiving ≥ 1 therapy (e.g. oxygen). Admitted singleton, twin and triplet neonates (triplet if demise before admission of ≥ 1 baby) weighing ≥ 700–≤ 2000 g and aged ≥ 1–< 48 h are eligible. Treatment allocation is random in a 1:1 ratio between groups, stratified by weight and recruitment site. The primary outcome is mortality within seven days. Secondary outcomes include mortality within 28 days, hypothermia prevalence at 24 h, time from randomisation to stabilisation or death, admission duration, time from randomisation to exclusive breastmilk feeding, readmission frequency, daily weight gain, infant–caregiver attachment and women’s wellbeing at 28 days. Primary analyses will be by intention-to-treat. Quantitative and qualitative data will be integrated in a process evaluation. Cost data will be collected and used in economic modelling.

(Continued on next page)
Background
An estimated 2.5 million neonatal deaths occurred in 2018, accounting for nearly half of all deaths in children aged <5 years [1]. Within the neonatal period, 36% of deaths occur on the day of birth and 73% occur in the first week [2]. Over 80% of neonatal deaths occur in low birthweight (LBW; weighing <2500 g) babies, of which two-thirds are born preterm (<37 weeks gestational age) [3]. Complications of prematurity are the leading cause of neonatal and under-5 mortality [1]. Approximately two-thirds of the 21 million LBW and 15 million preterm babies born each year are born in sub-Saharan Africa or southern Asia [4–6]. Together, these two regions are responsible for 78% of neonatal deaths [1]. With rates of preterm birth rising or stagnant across the globe [5, 6], finding ways to improve survival and reduce morbidity in preterm babies is a growing imperative.

Substantial progress could be achieved by improving facility-based care of small and sick babies in low- and middle-income countries (LMIC) [7, 8]. Estimates suggest that available interventions could reduce prematurity-related mortality by 58% [9]. Kangaroo mother care (KMC) is an intervention consisting of early skin-to-skin contact, promotion of exclusive breastfeeding, early hospital discharge, and adequate support and close follow-up at home [10]. The latest Cochrane review (21 trials) and a meta-analysis (124 studies) demonstrated that KMC among stable neonates ≤2000 g is associated with decreased mortality [11, 12], sepsis [11, 12], hypothermia [11, 12], hypoglycaemia [12] and length of stay [11] compared to conventional care. WHO guidelines recommend KMC for ‘routine care of newborns weighing ≤2000g... initiated as soon as newborns are clinically stable’ [13]; however, there is significant variability in how stability has been defined in previous randomised controlled trials (RCT) of KMC [14].

The majority of neonatal deaths occur within 48 h of birth [2], and before stabilisation. The only RCT of KMC initiated before stabilisation with mortality outcomes was conducted in Ethiopia, enrolling 123 newborns weighing <2000 g [15]. It reported a 43% reduction in mortality; however, 66% of deaths and the major difference between arms occurred within 12 h of birth [15, 16]. Further, this trial excluded >50% of eligible neonates, did not utilise allocation concealment and had an apparent group imbalance at baseline (favouring KMC) [15], compromising robustness. Hence, the effect of initiating KMC before stabilisation remains an unaddressed research priority and a well-designed RCT, with clear criteria for stability, is warranted to examine mortality impact in non-intensive care settings [16, 17]. The OMWaNA trial aims to determine the effect of KMC initiated before stabilisation on mortality within 7 and 28 days relative to standard care at four hospitals in Uganda.

There are few published economic evaluations of KMC, and none conducted rigorously in low-resource settings from a societal perspective or with systematic equity assessment. Several studies in LMIC settings have found that KMC resulted in cost savings for the hospital or provider [18–21]; however, none has considered whether KMC may increase costs to households nor purposely evaluated KMC initiated before stabilisation. Evidence gaps remain with regards to estimation of the incremental cost, cost-effectiveness, budget impact and equity of KMC before stabilisation, particularly considering the household and societal perspectives. An economic evaluation embedded within the trial will compare the incremental cost and cost-effectiveness of KMC relative to standard care.

Rigorous studies examining causal pathways for the effects of KMC on neonatal health outcomes have not been conducted; thus, scientific understanding is limited. Potential underlying mechanisms may include improved thermal control [11, 12], enhanced cardiorespiratory stability [22, 23], increased breastmilk volume [24, 25], oxytocin-mediated attenuation of the stress response [26, 27] and thermally mediated reduction in the risk of intraventricular haemorrhage (IVH) [28]. The relevance of these hypothesised causal pathways in neonates for whom KMC is initiated before stabilisation is unclear, particularly IVH risk among very low birthweight
(VLBW; < 1500 g) newborns. Incubators, which are the standard alternative to KMC, may increase the risk of nosocomial infections, particularly in newborn units with ineffective cleaning standards or where incubators are shared [29, 30]. Thus, further research is warranted to improve scientific understanding of the physiological processes underlying the effect of KMC relative to standard care in this vulnerable population.

**Methods/design**

This manuscript has been prepared according to the Standard Protocol Items: Recommendations for Interventionsal Trials (SPIRIT) statement (Additional file 1).

**Objectives**

The primary objective of the OMWaNA trial is to determine the effect of KMC initiated before stabilisation on mortality within seven days relative to standard care among neonates weighing ≤ 2000 g. Secondary objectives include:

1. Determining the effect of KMC initiated before stabilisation on other important clinical outcomes relative to standard care among neonates weighing ≤ 2000 g;
2. Estimating the incremental costs and cost-effectiveness of KMC initiated before stabilisation relative to standard care from the societal perspective;
3. Exploring hypothesised causal pathways for the clinical effects of KMC initiated before stabilisation relative to standard care among neonates weighing ≤ 2000 g;
4. Examining the barriers and facilitators to initiating KMC before stabilisation to inform uptake and sustainability in Uganda.

**Study design**

This is a four-centre, open-label, individually randomised, superiority trial with two parallel groups: an intervention arm allocated to receive KMC and a control arm allocated to receive standard care. Treatment allocation is random in a 1:1 ratio between groups.

**Study setting**

The host institution for the trial is the Medical Research Council/Uganda Virus Research Institute (MRC/UVRI) and London School of Hygiene & Tropical Medicine (LSHTM) Uganda Research Unit in Entebbe. The trial is being undertaken in collaboration with Makerere University and LSHTM. The trial is being conducted at four Ugandan government hospitals: Entebbe, Jinja and Masaka Regional Referral Hospitals and Iganga District Hospital (Fig. 1).

Uganda has a population of 42.9 million and is ranked 162/189 on the Human Development Index (2017) [31]. The population is predominately rural (76%) and the poverty incidence is 27% nationally [32]. Poverty rates vary considerably, with the highest rates occurring in rural areas where subsistence farming is the primary source of income. The Busoga sub-region, where Jinja and Iganga are located, has the third highest incidence of poverty in the country (42.1%), while the Wakiso sub-region, where Entebbe is located, has the second lowest (7.5%) [32].

In Uganda, the neonatal mortality rate is estimated at 19.9 per 1000 live births, with a resultant 32,296 deaths in 2018 [1]. Complications of prematurity are responsible for 27% of neonatal deaths [33], as compared to 35% globally [1]. An estimated 107,921 (7%) Ugandan babies were born preterm in 2014 [5].

Characteristics of the four trial hospitals are shown in Table 1. Each hospital has a neonatal special care unit, which accepts referrals from their respective region/district. The level of equipment in these government facilities differs, but all have: bag-mask resuscitation; incubators and/or overhead radiant heaters for thermal support; intravenous (IV) fluids, nasogastric tubes and syringes for feeding support; oxygen supply (concentrators or cylinders) and nasal prongs for respiratory support; IV and oral antibiotics; phototherapy for jaundice; aminophylline for prematurity-associated apnoea; and phenobarbital for seizures. Pulse oximetry and improved bubble continuous positive airway pressure (CPAP) ventilation are available at some of the trial hospitals. Invasive ventilation and surfactant are unavailable at all sites. Standard care at the four sites involves provision of intermittent KMC to neonates weighing ≤ 2000 g once stable, in line with current WHO guidelines.

**Study population**

The trial will include admitted neonates weighing ≤ 2000 g for whom the indication for KMC is ‘uncertain’ according to WHO guidelines concerning clinical stability [10]. Eligibility criteria are listed below.

**Inclusion criteria:**

- Neonate admitted to trial hospital (inborn or outborn);
- Singleton, twin or triplet (if triplet pregnancy resulted in demise or stillbirth of ≥ 1 fetus);
- Birthweight ≥ 700 g and ≤ 2000 g;
- Chronological age ≥ 1 h and < 48 h at time of screening;
- Alive at time of recruitment;
- Parent/caregiver able and willing to provide KMC;
- Parent/caregiver willing to attend follow-up visit;
- Indication for KMC ‘uncertain’ according to WHO guideline concerning clinical stability: pragmatically defined as receiving ≥ 1 therapy: oxygen; CPAP; IV
fluids; therapeutic antibiotics (for suspected or confirmed infection); phenobarbital.

Exclusion criteria:
- Result of triplet or higher-order multifetal pregnancy (unless triplet pregnancy resulted in demise or still-birth of ≥ 1 fetus);
- Indication for KMC ‘certain’ according to WHO guidelines: pragmatically defined as clinically well neonates receiving none of the above therapy-based criteria;
- Severely life-threatening instability defined as oxygen saturation (SpO₂) < 88% in oxygen and ≥ 1 of:
  - Respiratory rate < 20 or > 100 breaths/min;
  - Apnoea requiring bag-mask ventilation;
  - Heart rate (HR) < 100 or > 200 beats/min;
- Severe jaundice requiring immediate management;
- Active neonatal seizures;
- Major congenital malformation;
- Parent does not provide written informed consent to participate in trial.

Study procedures
The schedule of procedures for the OMWaNA trial is outlined in Fig. 2.

Figure 3 describes the flow of participants from the time of screening through follow-up at 28–30 days.

Screening
All admitted neonates weighing ≤ 2000 g at the four trial hospitals will be screened for eligibility by a study nurse or medical officer (Fig. 3a, ‘Screening for eligibility’). Eligibility will be assessed as soon as possible after admission and once the baby is aged ≥ 1 h to allow for transition immediately after birth. This is in recognition of the large physiological changes that take place following delivery and that the stability of a newborn aged < 1 h may change rapidly and not accurately reflect their subsequent clinical trajectory. Trained study staff will ascertain chronological age and relevant pregnancy details by examining source documents and/or conducting a standardised maternal interview. Weight will be measured using the Seca™ 384 electronic weighing scale. A focused examination will be conducted to assess for the presence of major congenital malformations, severe jaundice and seizures.

Neonates for whom KMC is indicated per WHO guidelines (i.e. are considered ‘stable’) will be excluded and receive KMC as part of standard care (Fig. 3a, ‘Stable to receive KMC’). Neonates for whom the indication for
KMC is ‘uncertain’ per WHO guidelines (i.e. are ‘prior to stability’) will be further assessed. For those neonates who are found to meet eligibility criteria (Fig. 3a, ‘Screening for eligibility’), a trained member of the study staff will monitor HR and SpO₂ using a Masimo Rad-8© pulse oximeter for 10 min and measure respiratory rate manually by counting breaths for 1 min. Those found to meet the criteria for ‘life-threatening instability’ (Fig. 3a, ‘Too unstable’), or who have seizures or jaundice requiring treatment, will not be eligible for immediate recruitment and will enter a cycle of reassessment every 3 h. All will continue to receive clinically indicated treatments and cardiorespiratory monitoring at the discretion of the on-duty paediatrician, medical officer or nurse. If, during any reassessment within the first 48 h, a neonate is found to have improved and no longer meets exclusion criteria, recruitment may proceed. Neonates who continue to have life-threatening instability or meet other exclusion criteria by 48 h will be permanently excluded.

**Informed consent**
Written informed consent will be sought from the parents of all participants for the following: neonatal inclusion in the study; collection of sociodemographic and clinical data; and randomisation to a study arm. Consent will also be obtained for the possibility that the caregiver will provide continuous skin-to-skin contact, if randomised to that arm. Additionally, consent will be obtained for the collection of household socioeconomic and cost data, as well as data on infant-caregiver attachment and women’s wellbeing. Study medical officers or nurses will request informed consent. The preferred person to provide informed consent for neonatal involvement is the mother. If a mother is unavailable or too ill to provide consent, consent can be obtained from the father. Once the mother is available and feeling well enough, the informed consent process will be repeated to confirm her consent for her baby’s continued participation. An impartial and literate witness will be used during consent for non-literate parents, as per International Council for Harmonisation-Good Clinical Practice (GCP) guidance.

**Collection of baseline data**
Study staff will be trained in infection prevention and standard operating procedures (SOP) will detail infection prevention and standard operating procedures (SOP) will detail...
control measures for the use of study equipment to avoid contamination between participants. Axillary temperature will be measured with a digital thermometer in degrees Celsius; three measurements will be taken to enable calculation of the mean value. Respiratory rate will be measured manually by counting breaths for 1 min. Blood glucose will be measured with a capillary sample using the study glucometer. Head circumference (HC) will be measured and a physical examination will be conducted. Baseline clinical and anthropometric data will be collected as soon

| ENROLMENT:         | Baseline | Allocation | Post-allocation | Close-out |
|--------------------|----------|------------|-----------------|-----------|
| Eligibility screen | X        |            |                 |           |
| Informed consent   | X        |            |                 |           |
| Allocation         | X        |            |                 |           |

| INTERVENTIONS: (KMC) |          |            |                 |           |
|---------------------|----------|------------|-----------------|-----------|
| Control             |          | X          |                 |           |

| ASSESSMENTS:        |          |            |                 |           |
|---------------------|----------|------------|-----------------|-----------|
| Clinical review²    | X        |            | X X X X X X X X |           |
| Heart rate¹        |X         |            |                 |           |
| Oxygen saturation¹  |X         |            | X X X X X X X X |           |
| Temperature¹        | X        |            | X X X X X X X X |           |
| Respiratory rate¹   | X        |            | X X X X X X X X |           |
| Blood glucose⁶      | X        |            | X X X X X X X X |           |
| Physical examination| X        |            |                 |           |
| Gestational age     |          | X          | X X X X X X X X |           |
| Weight⁶             | X        |            |                 |           |
| Crown-foot length   | X        |            | X X X X X       |           |
| Head circumference  | X        |            | X X X X X       |           |
| Socioeconomic data¹ | X        |            |                 |           |
| Cranial ultrasound² | X        |            |                 |           |
| WCI questionnaire³  | X        |            |                 |           |
| MIRI questionnaire⁴ | X        |            |                 |           |
| Outcome variables:  |          |            |                 |           |
| All-cause mortality | X        |            |                 |           |
| Hypothermia         | X        |            |                 |           |
| Time to death/stability | X    |            |                 |           |
| Time to exclusive breastfeeding | X  |            |                 |           |
| Duration of admission¹¹ | X      |            |                 |           |
| Readmission frequency |       |            |                 |           |
| Daily weight gain   | X        |            |                 |           |
| Women’s well-being⁵ | X        |            |                 |           |
| Infant attachment¹⁸ | X        |            |                 |           |

Fig. 2 OMWaNA trial schedule of enrolment, interventions and assessments. The start of trial procedures (time 0) is defined as when the pulse oximeter is attached for cardio-respiratory monitoring. All participants are reviewed daily while admitted to the hospital. Continuous monitoring continues until participants no longer require any form of respiratory support. HR, SpO₂, axillary temperature and respiratory rate are measured every 6 h until stability criteria are met, after which the frequency transitions to daily. Blood glucose is measured daily and may be discontinued once the participant tolerates full enteral feeds. Participants are weighed on day 5, then daily until discharge (unless deemed too unstable by site study staff). Socioeconomic data, including household details, are collected within 48 h of enrolment. During this time, study staff also inform families that they will be asked about their household expenditures and activities over the coming month. For participants at Entebbe and Jinja Hospitals, cranial ultrasounds are performed on days 1, 3 and 7 of hospitalisation (or as an outpatient if discharged before day 7) and on follow-up at day 28–30. The Women’s Capabilities Index (WCI) is administered to all mothers within 48 h of enrolment and on days 28–30 to assess women’s wellbeing. The Maternal Infant Responsiveness Instrument (MIRI) is administered on days 28–30 to assess infant-caregiver attachment. Duration of admission is measured as the mean time (days and hours) from hospital admission to discharge.
**Too unstable: repeat exam, vital signs every 3h up to 48h**
- Life-threatening instability:
  - Defined as SpO₂ <88% in oxygen AND ≥1 of:
    - Respiratory rate <20 or >100 breaths/minute
    - Apnoea requiring bag-mask ventilation
    - HR <100 or >>200 beats/minute
  - Active seizures
  - Jaundice requiring treatment

**Too unstable: excluded**

**Stability improved**

**Intervention arm**
- Continuous skin-to-skin contact initiated as soon as possible

**Routine procedures**
- **First 24h**
  - Continuous:
    - HR and SpO₂
    - Every 6 hours:
      - Axillary temperature
      - Respiratory rate
      - Blood glucose

**24h to discharge**
- Every 6h until stable then daily: HR, SpO₂, resp. rate, temperature
- Daily through day 7 then weekly (days 14, 21, 28):
  - IV fluids/feeding status
  - Therapies/medications
  - Blood glucose
- Daily weight from day 5
- Weekly HC and length
- Cranial ultrasound on days 1, 3, 7 (EH, JH)

**Fig. 3A. Screening for eligibility**
- Birthweight ≥700 and ≤2000g
- Chronicage age <48h
- Singleton, twin, or triplet (if ≥1 demise)
- Parent willing to provide KMC
- No major congenital malformation

**Stable to receive KMC as standard care (excluded)**
- Not receiving oxygen, CPAP, IV fluids, therapeutic antibiotics, or phenobarbital

**Informed consent**

**Baseline data collection**
- Temperature, respiratory rate, blood glucose, gestational age, length, HC, socioeconomic, WCI

**Randomisation**

**Control arm**
- Standard care in incubator or radiant heater, routine KMC once stable

**Routine procedures**
- **First 24h**
  - Continuous:
    - HR and SpO₂
    - Every 6 hours:
      - Axillary temperature
      - Respiratory rate
      - Blood glucose

**24h to discharge**
- Every 6h until stable then daily: HR, SpO₂, resp. rate, temperature
- Daily through day 7 then weekly (days 14, 21, 28):
  - IV fluids/feeding status
  - Therapies/medications
  - Blood glucose
- Daily weight from day 5
- Weekly HC and length
- Cranial ultrasound on days 1, 3, 7 (EH, JH)

**Fig. 3B. Signs of severe illness**
- Feed refusal/intolerance or distension
- Lethargy (responds only with stimulation)
- Respiratory rate >60 or severe chest in-drawing or increased resp. support
- Apnoea (new onset or persistent)
- Temperature (T) <35.5 or >37.5°C
- Active seizures

**Fig. 3C. Suspected infection criteria**
- ≥1 of above plus 1 of: jaundice, hepatomegaly, pallor, leathargy, apnoea, T <35.5 or >37.5°C

**Fig. 3D. Criteria for stopping KMC**
- Life-threatening instability (see above)
- Active seizures
- Jaundice requiring treatment
- Anaemia requiring blood transfusion
- Severe abdominal distension
- Omphalitis or widespread skin infection

**No**
- Continue KMC

**Yes (≥2 criterion met)**
- Temporarily withdrawn from KMC; standard care until meets restart criteria

**Follow-up visit at 28-30 days**
- Telephone call +/− home visit if non-attendance
- Document outcome, feeding status, anthropometry
- Administer MIRI and WCI questionnaires
- Perform cranial ultrasound (EH, JH only)

---

Fig. 3 (See legend on next page)
Neonates in the intervention group will receive KMC initiated as soon as possible after randomisation.

Randomisation, allocation and blinding

Treatment allocation is random in a 1:1 ratio between groups using permuted blocks of varying block sizes. The allocation sequence was computer-generated centrally at MRC/UVRI by an independent statistician, stratified by birthweight (< 1000, 1000–1499 or ≥ 1500 g) and recruitment site. The random allocation sequence is uploaded onto the REDCap (Research Electronic Data Capture, Nashville, TN, USA) platform [36] and accessed using a computer with Internet access at each site. The randomisation server and research database are hosted at the MRC/UVRI and LSHTM Unit data centre. This precludes any possibility of study staff viewing the allocation sequence. Allocation is revealed only after the study medical officer or nurse has entered all required screening data into REDCap. The mother is the unit of randomisation; twin and triplet participants will be allocated to the same arm. Each site has one spare computer in case of breakdown or theft; if both fail, the site will revert to random allocation using telephone as the back-up option. Given the nature of the KMC intervention, blinding parents/caregivers is not possible. Process and outcome data will be anonymised and all analyses will be blinded. Analyses will be unblinded for the Data and Safety Monitoring Board (DSMB) at their request.

Intervention arm

Neonates in the intervention group will receive KMC initiated as soon as possible after randomisation. Neonates will be naked except for hat and diaper, and will be secured to the exposed chest of the caregiver using a KMC wrap (Fig. 4a). The caregiver is seated or lying on a bed, while the neonate receives any clinically indicated therapies (e.g. IV fluids, antibiotics, oxygen). Caregivers will be encouraged to provide KMC as close to continuously as possible, aiming for at least 18 h per day. If the primary caregiver is unavailable, another family member (e.g. father, grandmother) or close friend (helper) will be encouraged to provide KMC. If a family member or helper is not available to continue KMC, the neonate will be placed into an incubator or under a radiant heater until the caregiver returns. KMC will continue to be encouraged until discharge and at home after discharge, as per WHO guidelines. KMC is commonly practiced until the baby is 2500 g or resists the KMC position, which is often at 4–10 weeks after birth.

Neonates who meet any of the criteria for stopping KMC (Fig. 3d, ‘Criteria for stopping KMC’) will be temporarily withdrawn from the intervention and cared for in an overhead heater or incubator at the discretion of the on-duty paediatrician. KMC may be restarted once all of the following criteria are met: (1) no longer meet any of the stopping criteria; (2) no apnoea requiring bag-mask ventilation for 24 h; (3) not on phototherapy; (4) no seizures for 24 h; (5) no abdominal distension; (6) caregiver available and willing to do KMC; (7) no healthcare worker concerns about clinical condition.

Control arm

Neonates in the control group will be cared for in an incubator (Fig. 4b) or under a radiant heater. Caregivers are able to touch, hold and feed their baby, but may not provide any skin-to-skin contact until the neonate meets WHO criteria for KMC, i.e. are considered ‘stable’. Neonates will be considered stable when the following criteria have been met for a continuous period of ≥ 24 h: (1) breathing spontaneously with SpO₂ > 90% in room air; (2) no need for supplemental oxygen or CPAP; (3) respiratory rate 40–< 60 breaths/min; (4) no apnoea; (5) HR 80–< 180 beats/min; (6) axillary temperature 36.0–37.4 °C; and (7) no need for IV fluids. These criteria are consistent with those being used in the WHO-led Immediate KMC (I-KMC) trial [37]. Once stable, neonates can transition to routine (intermittent) KMC with the caregiver in line with standard care at the...
trial sites. As in the intervention arm, neonates in the control arm who meet any of the criteria for stopping KMC (Fig. 3d, ‘Criteria for stopping KMC’) will be cared for in an overhead heater or incubator until re-start criteria are met.

Participant flow around study sites
Participant flow around the study sites is illustrated in Fig. 5, using Entebbe Hospital as an example. All neonates are initially stabilised and assessed at a radiant heater. While clinically ‘unstable’, neonates allocated to KMC are cared for in a study bed and those allocated to standard care are cared for in an incubator or radiant heater. Participants in both arms are transferred to the KMC step-down unit once they meet stability criteria.

Neonatal care capacity building
Substantial expansion of neonatal care capacity and infrastructure at all trial sites has been embedded within the OMWaNA trial. This includes enlargement of the KMC areas within the neonatal units to ensure...
that all neonates, whether in KMC or not, can be cared for safely. Additional infrastructure improvements include sinks to provide an optimal environment for infection control, bathrooms/toilets for mothers/caregivers and office space for clinical staff. One study medical officer and 4–5 study nurses have been recruited to join the clinical teams at each site. Further, each site will be provided with the following supplies and equipment: six Masimo Rad-8© oximeters with neonatal sensors; one oxygen concentrator; two thermometers; one glucometer with blood glucose testing strips; one neonatal ventilation bag and mask; one Seca™ 210 neonatal weighing scale; one Seca™ 384 neonatal weighing scale; two paediatric stethoscopes; and a minimum of four adjustable beds. In addition, KMC wraps will be provided to support practice in each unit.

**Clinical care for neonates in both arms**

**Clinical monitoring**

All participants will be evaluated at least once by a study paediatrician or medical officer during the first 24 h after randomisation. All participants will receive continuous monitoring and recording of HR and \( \text{SpO}_2 \) for 72 h after randomisation. Continuous monitoring will continue until participants no longer require any form of respiratory support. HR, \( \text{SpO}_2 \), axillary temperature and respiratory rate will be measured and recorded by a study nurse every 6 h until stability criteria are met, after which the frequency will transition to daily. According to the same frequency, a study nurse will observe and record the presence or absence of clinical signs of respiratory distress, including chest in-drawing, nasal flaring and grunting. Blood glucose will be measured every 6 h during the first 24 h after randomisation unless it is \(< 2.6 \text{ mmol/L} \), in which case it will be measured hourly until two or more consecutive readings are in normal range \((2.6–6.9 \text{ mmol/L})\). Subsequently, blood glucose will be measured daily until a participant is tolerating full enteral feeds.

**Medical therapies**

All enrolled neonates will receive clinically indicated treatments, including but not limited to oxygen, IV fluids (given by bolus or burette), antibiotics, aminophylline, anticonvulsant medicines and phototherapy. Standardised clinical guidelines will be followed for common neonatal conditions, including preterm fluids/feeding (including breastfeeding), suspected and proven sepsis, respiratory distress, jaundice and seizures. Bubble CPAP will be provided at the discretion of the on-duty paediatrician at sites where this is the standard of care. Jaundice will be treated with phototherapy for neonates in both arms. All caregivers will be trained in KMC regardless of study arm.

**Clinical deterioration**

Neonatal unit staff at all sites will be trained to recognise signs of severe illness (Fig. 3b, ‘Signs of severe illness’) and to inform study staff if a participant meets any of these criteria. The study paediatrician or medical officer (or study nurse if neither is present) will examine the neonate as soon as possible to assess whether signs of early-onset \(< 72 \text{ h of age}\) or late-onset \((\geq 72 \text{ h of age})\) infection (Fig. 3c, ‘Suspected infection criteria’) are present. Neonates will be reassessed for signs of severe illness and infection during daily rounds. Where available, a blood culture will be obtained as soon as possible if a neonate meets criteria for suspected infection; however, this will not delay administration of antibiotic therapy. Study staff will also assess if the neonate meets criteria for temporary withdrawal from KMC (Fig. 3d, ‘Criteria for stopping KMC’). At the discretion of the study paediatrician, neonates may be referred to a higher-level facility for more specialised care; however, existing data indicate that this is an uncommon occurrence.

**Discharge and follow-up**

At the time of discharge, all caregivers will be provided with an illustrated handout on neonatal danger signs and instructed to contact the site study team or seek medical help if their baby becomes unwell. Caregivers of babies in both arms will be encouraged to continue KMC at home. All participants will be given an appointment to attend the follow-up clinic at the respective study site on days 28–30. At this visit, cranial ultrasound (Entebbe and Jinja Hospitals only) and anthropometry will be performed, feeding practices and outcomes (alive, dead, readmitted) will be documented, and the WCI and Maternal Infant Responsiveness Instrument (MIRI) questionnaires will be administered to mothers.

If participants are discharged before day 7, additional follow-up will be arranged according to study site. If participants do not attend the follow-up visit, a telephone call will be made the same day to ascertain outcome and feeding practices and to arrange follow-up, either in the clinic or at the families’ home, as soon as possible. Routine follow-up beyond the planned study follow-ups will be provided by the study staff according to standard practice and based upon the clinical need of the baby.

**Safety reporting and study monitoring**

Adverse events (AE) are medical events or laboratory findings, which result in a change in clinical management after randomisation and until 28 days after birth. A serious adverse event (SAE) is defined as an event that
result in death, is life-threatening, requires hospitalisation or prolongation of hospitalisation, results in persistent or significant disability, or requires intervention to prevent permanent impairment or damage [38]. Study medical officers and nurses will inform the site paediatrician about any SAE occurrence within 24 h. SAEs will be followed up by the paediatrician until their resolution or stabilisation, or until causality is determined to be unrelated to the trial intervention. If a serious but unexpected AE occurs, which might be related to the trial intervention, a SAE report will be submitted to the Research Ethics Committees (REC) at UVRI and LSHTM within 48 h of the investigators becoming aware of the event, with a follow-up report provided within a further five working days. This expedited reporting will be limited to those outcomes not already listed as primary or secondary outcomes, yet which might reasonably occur as a consequence of the trial intervention. All SAEs will be reported to the Sponsor and RECs as part of their respective annual progress and safety report.

The DSMB will oversee the overall integrity of the study, its safety and its continued relevance and ability to answer the primary objective. DSMB members include a perinatal epidemiologist/statistician (chair), a South African neonatologist and a neonatal bioethicist. The DSMB will receive a summary of SAEs after one month of recruitment, then move to every three or six months; the DSMB will decide the frequency following the first report. An interim analysis will be performed on the primary outcome when approximately half of neonates have been randomised. An independent statistician will perform the interim analysis, blinded to treatment allocation and report to the DSMB. Analyses will be unblinded at the request of the DSMB. In light of these data and other evidence from relevant studies, the DSMB will inform the Trial Steering Committee (TSC) if in their view; it is evident that no clear outcome will be obtained with the current trial design; they have a major ethical or safety concern; or it is evident that the intervention is clearly superior and continuing the trial would be unethical to those in the control arm. The TSC will make the final decision on study continuation.

The study will be monitored by the Reciprocal Monitoring Scheme of the East African Consortium for Clinical Research in collaboration with the Research Compliance and Quality Assurance section of the MRC/UVRI and LSHTM Unit. Dedicated study monitors, independent of the study team, will oversee progress and ensure the trial is conducted and data are handled in accordance with the protocol, SOPs and applicable ethical and regulatory requirements. In addition, the UVRI REC will conduct initial site visits with neonatal specialists from the Uganda Paediatrics Association and the Ugandan Ministry of Health Newborn Steering Committee. The trial may be subject to audit by LSHTM under their remit as Sponsor, the Study Coordination Centre and other regulatory bodies to ensure adherence to GCP.

Outcome measures

The primary outcome is all-cause early neonatal mortality (within seven days). Estimates suggest that three-quarters of neonatal deaths occur in the first week of life [2]. Secondary outcomes are as listed below.

1. **Prevalence of hypothermia (axillary temperature < 36.5 °C) at 24 h after randomisation**
   - Axillary temperature will be assessed using a digital thermometer.

2. **Time from randomisation to clinical stabilisation (days and hours)**
   - The date and time of randomisation and clinical stabilisation will be prospectively recorded. Stability is defined as having met all of the following criteria for a continuous period of at least 24 h:
     - Breathing spontaneously with SpO₂ > 90% in room air;
     - No need for supplemental oxygen or CPAP;
     - Respiratory rate 40–60 breaths/min;
     - No apnoea;
     - HR 80–180 beats/min;
     - Axillary temperature 36.0–37.4 °C;
     - No need for IV fluids.

3. **Time from randomisation to death (days and hours)**
   - The date and time of death will be prospectively recorded from the death certificate for in-hospital deaths. For deaths occurring after discharge, the date will be recorded according to verbal report by the parent/caregiver.

4. **Time from randomisation to exclusive breastfeeding (days and hours)**
   - The date and time of randomisation and initiation of exclusive breastfeeding will be prospectively recorded. Exclusive breastfeeding is defined as receiving breastmilk, either directly from the breast or by nasogastric tube, bottle, cup or spoon after expression from the breast, as the sole source of nutrition [39].

5. **Mean duration of hospital admission (days and hours)**
   - The date and time of admission and discharge will be documented prospectively for the first admission episode.

6. **All-cause mortality within 28 days**
   - This outcome will be documented at the follow-up visit on days 28–30. If participants do not attend, a telephone call will be made the same day to ascertain outcome.

7. **Mean frequency of readmission at 28 days**
Episodes in which a neonate who had been discharged from a hospital is readmitted to the same hospital during the first 28 days will be prospectively recorded. Episodes in which a neonate is readmitted to a different hospital will be recorded according to verbal report by the parent/caregiver on follow-up at days 28–30.

8. **Mean daily weight gain (g/day) at 28 days**
Mean daily weight gain will be calculated as the difference between weight at enrolment and on follow-up at days 28–30, as measured by the study scale.

9. **Women's wellbeing at 28 days**
Women’s wellbeing will be assessed using the WCI, a capability-based composite measure of quality of life that will capture the broader effects to the mother of practicing KMC. The WCI includes six domains (physical strength, inner wellbeing, household wellbeing, community relations, economic security, happiness), with a total of 26 sub-dimensions [40]. Developed and validated in Malawi, the WCI was recently adapted for use in Uganda [41].

10. **Infant–caregiver attachment at 28 days**
Infant–caregiver attachment will be assessed using the MIRI, a 22-item questionnaire that measures maternal recognition of responsiveness to infant cues, maternal recognition of infant responsiveness and difficulties in responsiveness [42]. The MIRI was developed and validated in the United States, and is now being used in Uganda [43].

### Process outcomes
Understanding the hypothesised causal pathways for clinical effects of the intervention (objective 3) will be achieved by measurement of the following process outcomes, which are categorised as providing very early (within 24 h), early (within 72 h) or late clinical impact.

1. **Cardiorespiratory stability within 24 h, 72 h after randomisation**
Proportion of time spent with suboptimal HR (<100 bpm) and SpO2 (<85%) over the first 24 h and 72 h after randomisation, measured and recorded continuously using the study pulse oximeter.

2. **Prevalence of hypothermia (axillary temperature < 36.5 °C) at 24 h, 72 h after randomisation**
Axillary temperature will be assessed using a digital thermometer.

3. **Hypothermia density within 24 h, 72 h after randomisation**
Hypothermia density is defined as the proportion of time the axillary temperature is < 36.5 °C during a defined time period. Axillary temperature will be measured every 6 h during the first 24 h after randomisation and until clinically stable, after which it is measured daily.

4. **Prevalence of hypoglycaemia (blood glucose < 2.6 mmol/L) within 24 h, 72 h after randomisation**
Blood glucose will be measured using a study glucometer and glucose testing strips.

5. **Presence and severity of IVH at 72 h, seven days after randomisation; presence of late intracerebral sequelae of prematurity at days 28–30**
IVH is a complication of prematurity characterised by bleeding within the cerebral ventricles, typically originating from the periventricular germinal matrix; severity ranges from grade 1 (mild) to grade 4 (severe) [44]. Late intracerebral sequelae include cystic degeneration, post-haemorrhagic hydrocephalus and cerebral atrophy. The study paediatrician or medical officer at two of the four hospitals (Entebbe and Jinja) will perform cranial ultrasounds using a Sonosite Edge II™ portable ultrasound machine. Both standard and linear probes will be used to assess for abnormalities according to a defined protocol and will include ≥11 coronal and sagittal views. Images will be read by an independent expert.

### Data collection, management and security
Trial data will be electronically entered into trial-specific case report forms on tablets using an offline, mobile REDCap application, with inbuilt ranges and consistency checks. Data from tablets will be synchronised once daily over a secure connection with the web-based REDCap database, hosted at the MRC/UVRI and LSHTM Unit data centre. Cardiorespiratory data from Masimo Rad-8® oximeters will be downloaded using Stowood Visi-Download™ software, captured in CSV files, securely transmitted to MRC/UVRI, analysed with PROFOX™ software and reconciled with the trial database. Cranial ultrasound images will be stored in OsiriX Dicom™ software and interpreted blind to allocation and clinical details. Logs linking parent/caregiver names and residence location will be stored separately on password-protected computers, with a hard copy stored in locked cabinets in secure rooms at all sites.

All data will be stored in institutional servers at the MRC/UVRI and LSHTM Unit during the study. Data from the web-based REDCap database will be downloaded and stored on institutional servers at LSHTM in London for access by the PIs and independent statistician for analysis and preparation of reports for the DSMB, respectively. These secure, password-protected servers are only accessible within the LSHTM network and activity is fully audited, recording both login details and file system access. Access will be limited to essential research personnel.
Sample size
Assuming a control mortality rate of 25% across the four recruitment sites, 1750 neonates (875 per arm) would enable us to detect a relative difference between arms of 22.4% (5.6% absolute difference) with 80% power and a significance level of 5%. If the control mortality rate were in fact as low as 18%, we would still be able to detect a relative difference of 27% (absolute difference of 4.8%). We plan to recruit 2188 neonates (1094 per arm) in order to allow for 10% withdrawal due to clinical deteriorations and consent withdrawal, and 10% dilution due to non-compliance and loss to follow-up. This sample size would enable us to detect absolute reductions of 6.3% and 5.4% from control rates of 25% and 18%, respectively, with 90% power.

Statistical analyses
Summary of baseline data and flow of patients
Baseline characteristics of enrolled neonates will be summarised by treatment arm. Descriptive statistics for continuous variables will include mean, standard deviation, median, range and number of observations. Categorical variables will be summarised as counts and proportions. Participant flow through screening, randomisation, allocation and follow-up will be illustrated in a CONSORT diagram (Fig. 6), with reasons for exclusion, non-adherence, loss to follow-up and non-analysis documented.

Primary and secondary outcome analyses
Primary and secondary outcome analyses will be carried out on all neonates as randomised (‘intention-to-treat’). The rate of loss to follow-up will be reported. We will report risk ratios for mortality within seven days (primary outcome) and 28 days (secondary outcome) for intervention versus control with associated 95% confidence intervals (CI). Time from randomisation to death, time from randomisation to exclusive breastmilk feeding and length of stay will be analysed using Kaplan–Meier plots and hazard ratios, with accompanying 95% CI calculated using Cox proportional hazards regression. All other secondary outcomes will be analysed using appropriate regression models accounting for the nature of the distribution of the outcome, and results will be presented as appropriate effect sizes with a measure of precision (95% CI). Both unadjusted analyses and analyses adjusted for stratification factors will be carried out. Additional exploratory analyses will control for any baseline measures that appear to be imbalanced between arms.

Subgroup and adjusted analyses
Subgroup analyses are planned to explore between-group differences in the impact of KMC relative to standard care on mortality by gestational age (<28, 28–32 or >32 weeks), birthweight (<1000, 1000–1499 or ≥1500 g) and recruitment site. Gestational age is an important predictor of newborn survival. In settings with newborn special care without intensive care, such as the four trial hospitals, neonatal mortality rates are 86% in neonates born at <28 weeks and 41% in neonates born at 28–31 weeks [43]. Further exploratory analyses will be carried out to explore the association between mortality and time of initiation (<12, 12–< 24 or ≥24 h), and continuity of KMC (median hours per day: <6, 6–<12, 12–<18 or 18–24 h).

Process evaluation
The process evaluation is being conducted to strengthen understanding of KMC initiation before stabilisation on neonatal health outcomes, considering both intended (beneficial) and unintended (negative) clinical effects. Changes in neonatal care between hospitals and from before the trial will also be assessed. This evaluation will be conducted in accordance with the MRC guidance on process evaluation of complex interventions [46], and will integrate quantitative and qualitative data. Quantitative outputs will include data related to causal pathways for clinical effects, neonatal admissions data, and health system- and facility-level survey data. Quantitative data will be summarised using descriptive statistics. Qualitative data will be collected though in-depth interviews, focus group discussions and workshops with parents/caregivers, healthcare providers and other key stakeholders to identify experiences of KMC and explore facilitators and barriers to inform uptake and sustainability. These data will be analysed using a thematic content approach. An iterative methodology will be used with data collected at several time points and then used to inform later explorations. Intervention reporting will follow the template for intervention description and replication (TIDieR) [47], which will ensure a shared understanding of all activities related to the trial intervention and, if shown to be effective, how these relate to any proposed scale-up activities. In addition, the TIDieR will facilitate thoughtful consideration regarding the transferability of findings outside a trial setting and to other hospitals in Uganda and elsewhere.

Economic evaluation
The incremental cost, cost-effectiveness, budget impact and equity of KMC for neonates before stabilisation relative to standard care will be examined from both an aggregated and a disaggregated societal perspective (provider and household combined), in accordance with the reference case [48]. Effects of the intervention on neonatal health and maternal wellbeing will be assessed. Both financial costs, which reflect actual monies paid,
Assessed for eligibility (n=)
New admissions weighing ≥500g and ≤2000g

Excluded: (n=)
- Age <1h or ≥48h at time of screening
- Weight <700g or >2000g
- Result of triplet or higher multifetal pregnancy (unless triplet with ≥1 demise/stillbirth)
- Stable, indication for KMC “certain” per WHO guidelines (defined as receiving <1 of the following: oxygen, CPAP, IV fluids, therapeutic antibiotics, phenobarbital)
- Life-threatening instability (defined as SpO₂ <88% in oxygen and ≥1 of: resp. rate <20 or >100 breaths/min, HR <100 or >200 beats/min, apnoea requiring bag-mask ventilation)
- Severe jaundice requiring treatment
- Active seizures
- Major congenital malformation
- Parent/caregiver unable or unwilling to provide KMC
- Parent/caregiver unwilling to attend follow-up
- No parental informed consent
- Declined to participate
- Other reason

Randomised (n=)

Allocated to KMC (n=)
Received KMC (n=)
Did not receive KMC (give reasons) (n=)
- Consent withdrawal (n=)
  Withdrawal due to clinical deterioration (n=)
  Lost to follow-up (give reasons) (n=)
- Analysed (n=)
  Excluded from analysis (give reasons) (n=)

Allocated to standard care (n=)
Received standard care (n=)
Did not receive standard care (give reasons) (n=)
- Consent withdrawal (n=)
  Withdrawal due to clinical deterioration (n=)
  Lost to follow-up (give reasons) (n=)
- Analysed (n=)
  Excluded from analysis (give reasons) (n=)

Fig. 6 CONSORT flow diagram for the OMWaNA trial
and economic costs, which reflect the full value of resources used, will be examined. Multiple data sources will be triangulated to arrive at best estimates. Where possible, resource use and unit costs will be collected and presented separately, although some costs, such as out-of-pocket payments for transport, do not permit this. Household costs will be collected through surveys amongst a sample of caregivers at the time of discharge and during follow-up visits. Costs to providers will be collected prospectively and retrospectively using project accounts, key informant interviews, facility audits, direct observations and time-use surveys. As necessary, secondary data on costs of treating subsequent conditions may be supplemented with limited primary data collection in the trial hospitals. Costs and effects will be modelled using a lifetime time horizon.

Discussion

Deaths in the neonatal period are responsible for 47% of mortality in children aged <5 years [1]. Complications of prematurity are the leading cause, accounting for 35% of neonatal deaths and 16% of under-5 deaths [1]. The majority of neonatal deaths occur before stabilisation in settings without intensive care [2]. The OMWaNA trial will measure the impact of KMC initiated before stabilisation on mortality within seven days at four neonatal units in Uganda, where intensive care is not available. With rates of preterm birth and institutional delivery on the rise globally [5, 6, 49], this intervention has the potential to benefit an ever-growing number of neonates. This trial was designed with an aim to align clinical criteria and data definitions to facilitate future opportunities for pooled analyses with related RCTs, including the eKMC trial in The Gambia [50] and the multi-country I-KMC trial led by WHO [37]. Several challenges were identified over the course of designing the OMWaNA trial, the most notable of which are related to informed consent and recruitment, non-adherence and contextual resource limitations.

Challenge 1: timely recruitment with informed consent

Obtaining timely informed consent for this RCT may be challenging given the involvement of sick neonates [51, 52], the fact that KMC needs to be started as soon as possible after birth and the fact that some women may be too ill, especially within the first 24 h, to provide consent or participate. In addition, some of these women may not be literate. Parental stress is compounded by the fact that complications may be unexpected, especially in low-resource settings, where knowledge of preterm birth is generally low. To help address these issues, the OMWaNA trial utilises the continuous consent approach [53], which involves providing information at multiple time points both before and after recruitment. Studies have found that the validity of consent improves when discussion continues after recruitment [53]. This approach has three main elements:

1. Parents will be given preliminary information during neonatal eligibility screening;
2. If the neonate is eligible, a comprehensive information sheet will be provided, and further discussion will take place. If the parents express willingness and ability to participate, written informed consent will be obtained and the neonate will be randomised;
3. During the intervention period, study staff will meet with parents to ensure that they understand the trial procedures and wish to continue to participate in the trial. It will be made clear that they may withdraw their baby from the trial at any time.

Audit data from the feasibility study at Jinja Hospital suggest that ~ 400 eligible neonates are admitted annually [14]. Preliminary data suggest that ~ 500 eligible neonates are admitted to Iganga and Entebbe Hospitals per year and ~ 800 eligible neonates are admitted to Masaka Hospital per year. Thus, a total population of ~ 4400 eligible neonates is expected over the 24-month recruitment period, which means a recruitment rate of ~ 50% will be required to achieve the target sample of 2188. The feasibility study findings suggest that this is realistic and achievable [14]. The trial timeline includes a three-month buffer period in the event that recruitment is delayed or slower than expected. Further, training of study staff emphasised the importance of timely reporting and responsiveness to recruitment issues.

Challenge 2: non-adherence to allocated treatment, especially continuous KMC

Among neonates in the control group, non-adherence with allocation (e.g. parents demanding early KMC) is a potential issue; however, this has not been reported in other trials [11]. Adherence in both arms, particularly the KMC arm, could be affected by parents witnessing a death (e.g. in the KMC position). Some babies will die regardless of the trial arm to which they are randomised. Preterm neonates can die quickly, even in settings with intensive care, and such deaths are a recognised impediment to KMC [54]. Stigma regarding preterm birth is common in Uganda, but has not impeded KMC practice for stable babies [55]. Study staff will counsel parents about the potential for mortality at the time of enrolment as well as counsel parents of neonates who die and those who witness a death. In addition, prompt reporting of all SAEs and trial monitoring through regular site visits will further facilitate timely identification of and responsiveness to any compliance issues, should they arise.
Adherence to the target duration of KMC (≥ 18 h/day) may be challenging [56]. Among five RCTs that promoted continuous KMC, three reported durations of ≥ 20 h/day [18, 57, 58] and two did not report duration [15, 59]. Among 16 RCTs evaluating intermittent KMC in stable neonates, one reported mean/median duration of 17 h/day, five reported 10–14 h/day and nine reported < 10 h/day [60]. The OMWaNA trial will employ a comprehensive approach to improve adherence. An illustrated KMC handout will be provided to caregivers at the time of enrolment. Study staff will counsel mothers about the benefits of KMC throughout the hospital stay, including the time of discharge. Studies have noted the importance of staff training and counselling for KMC [61, 62], and a related RCT demonstrated the efficacy of peer-counselling in promoting breastfeeding among hospitalised preterm neonates [63]. We will establish KMC peer-counselling programmes at each site, enlisting mothers who practiced KMC as participants when they return for follow-up. Peer counselling will address many maternal concerns and may help facilitate longer durations of KMC. We will also engage hospital administrators about KMC guidelines. Adjustable beds and KMC wraps will be provided, as these have been shown to improve adherence [56]. Lack of privacy and inadequate space for beds and equipment were identified as significant barriers to KMC practice in the feasibility study [14]. Provision of increased space within the four neonatal units may facilitate caregiver privacy as well as help improve clinical providers’ ability to safely care for at-risk neonates. Despite these measures, this is a pragmatic trial and some non-adherence is inevitable. The effect of non-adherence might be to dilute the size of the effect of KMC (assuming it ‘works’) and this has been factored into the sample size calculations. Biannual neonatal quality of care surveys, including progress monitoring of KMC provision/services, will be conducted at the four sites as part of the process evaluation.

Challenge 3: context including infrastructure, supplies and equipment

Over the six months preceding the start of the trial, the study team has made extensive efforts to expand neonatal care capacity at the four hospitals. Improvements include increased space and water supply in the neonatal units, office space for clinical staff, bathrooms/toilets for caregivers, adjustable beds for KMC, and various equipment and supplies. Despite these efforts, context-related resource constraints are inevitable. In government facilities, such as the four trial hospitals, supply/medication shortages are common and repair of malfunctioning equipment (e.g. incubators, oxygen concentrators) is often protracted. Triannual (every four months) surveys of staffing, equipment, supply and medication availability, and infrastructure across the sites are included in the process evaluation. In addition to the supplies and equipment provided before trial commencement, the budget includes a small allowance to help cover the cost of necessary commodities for each participating neonate.

Electrical power is required for incubators, radiant warmers, oxygen concentrators and phototherapy. Lack of access to reliable electricity is a problem in many LMICs, including Uganda, where a 2007 national survey showed that only 19% of government hospitals had reliable electricity (during working hours) or a backup generator with fuel [64]. In 2014, a study at Jinja Hospital recorded 120 episodes of power failure (mean of 13 times/week), with a median duration of 30 min each, over a 64-day period [65]. The four trial hospitals have reliable power supply, with occasional brief power outages (e.g. when back-up generators run out of fuel). Daily communication between staff at the MRC/UVRI and LSHTM Unit and the sites will facilitate timely identification and resolution of any significant power outages impacting patient care. Frequency and duration of power outages will be recorded by site staff.

Conclusion

The OMWaNA trial will assess the effectiveness of KMC in reducing mortality among neonates before stabilisation, a population where the benefits of KMC are currently uncertain. These findings are expected to have broad applicability to hospitals in low-resource settings and important policy and programme implications. The trial will be among the first to rigorously compare the incremental cost and cost-effectiveness of KMC and standard care, taking into account family members’ time, which will be crucial to ensure the sustainability of this intervention. Additionally, OMWaNA will advance understanding of the underlying mechanisms for the effects of KMC before stabilisation, including prematurity-associated brain injury, which could help inform prevention of disability as well as guide further innovation to improve survival for preterm newborns in the highest mortality settings.

Supplementary information

Supplementary information accompanies this paper at https://doi.org/10.1186/s13063-019-4044-6.

Additional file 1. SPIRIT checklist.
Additional file 2. LSHTM ethics letter.
Additional file 3. UVRI ethics letter.
Additional file 4. UNCST ethics letter.
Additional file 5. Funding documentation.

Abbreviations

AE: Adverse event; CI: Confidence interval; CONSORT: Consolidated Standards of Reporting Trials; CPAP: Continuous positive airway pressure; DSMB: Data...
and Safety Monitoring Board; EH: Entebbe Hospital; GCP: Good Clinical Practice; HC: Head circumference; HR: Heart rate; IV: Intravenous; IVH: Intraventricular haemorrhage; JH: Jinja Hospital; KMC: Kangaroo mother care; LBW: Low birthweight; LMIC: Low- and middle-income countries; LSHTM: London School of Hygiene & Tropical Medicine; MRC: Medical Research Council; OMWaNA: Operationa lising kangaroo mother care before stabilisation amongst low birth Weight Neonates in Africa; PI: Principal investigator; RCT: Randomised controlled trial; REC: Research Ethics Committee; SAE: Serious adverse event; SOP: Standard operating procedure; SPIRIT: Standard Protocol Items: Recommendations for Interventional Trials; SpO₂: Oxygen saturation measured by pulse oximetry; TSC: Trial Steering Committee; UVRI: Uganda Virus Research Institute; WCI: Women’s Capabilities Index; WHO: World Health Organization

Acknowledgements

The formative work investigating the feasibility of KMC initiated before stabilisation was supported by awards from the University of California San Francisco Preterm Birth Initiative and the Thrasher Research Fund to Dr. Melissa Medvedev. The OMWaNA trial and protocol have been developed through a two-way collaboration with the eKMC trial investigators, and implementation experiences of the eKMC trial have been a valuable input to OMWaNA. We acknowledge Prof Elizabeth Molyneux, Prof Stefan Peterson, Dr. Rebecca Nantanda and Prof Adriano Cattaneo of the Trial Steering Committee, and Prof Maria Quigley, Dr. Natasha Rhoda and Prof Maureen Kelley of the DSMB. We thank Prof Pontiano Kaleebu for his support and commitment as Director of MRC(UVRI), the host institution for this trial. Thanks to Dr. Geoffrey Kibuugu, Dorothy Mirembe, Timothy Temerar, Ayoub Kakande and Haroon Yiga at MRC/UVRI for their assistance with regulatory, administrative and data management aspects of trial preparations. Thanks to Claudia DuŠšiva at LSHTM for assisting with project administration. Finally, we thank the medical directors (Dr. Moses Mwumwe, Dr. Edward Nkururuziza, Dr. Nathan Onyach, Dr. James Waako), paediatricians (Dr. Rolland Mutumba, Dr. Irene Naviga, Dr. Sheila Oyiella, Dr. Christine Shema) and nurse matrons of the neonatal units (Maburuka Anguparu, Agnes Batani, Gladys Bingi, Aya Esther) at Entebbe, I ganga, Jinja and Masaka Hospitals for their support and dedication throughout the trial preparation process.

Composition, roles and responsibilities of the TSC, DSMB, TMG and Study Implementation Team

Trial Steering Committee:
Chair: Prof Elizabeth Molyneux, University of Malawi, Blantyre, Malawi (retired); Members: Prof Stefan Peterson, United Nations Children's Fund, New York, USA; Dr. Rebecca Nantanda, Uganda Paediatric Association, Kampala, Uganda; Prof Adriano Cattaneo, WHO Collaborating Centre for Maternal & Child Health, Trieste, Italy (retired); with invited observers from the Trial Management Group.
Role: Oversight of trial conduct and progress towards its objectives; review at regular intervals relevant information from other sources; consent and review of DSMB reports with action as appropriate.

Data and Safety Monitoring Board:
Chair: Prof Maria Quigley, University of Oxford, Oxford, UK; Members: Dr. Natasha Rhoda, University of Cape Town, Cape Town, South Africa; Prof Maureen Kelley, University of Oxford, Oxford, UK.
Role: Monitor data for quality and completeness, and evaluate for any evidence of harm to participants.

Terms of the DSMB charter are available upon request from the OMWaNA PI (Prof Joy Lawn).

Trial Management Group:
Prof Joy Lawn (PI), Dr. Melissa Medvedev (co-PI), Dr. Peter Waiswa (co-PI), Dr. Cally Tann (co-PI), Prof Elizabeth Allen (co-PI), Prof Moffat Nyirenda (senior MRC/UVRI member), Prof Diana Elbourne (senior trial and ethics advisor), Dr. Victor Turkumude (site coordinator), Dr. Ivan Mambule (trial coordinator), Dr. Elizabeth Ekirapa-Kiracho (lead economist), Dr. Catherine Pitt (economic advisor).
Role: Monitoring of study progress; advice; implementation, publications and dissemination strategy.

Study Implementation Team:
Drs Melissa Medvedev and Cally Tann (on behalf of TMG), Ms. Ruth Canter (on behalf of LSHTM Clinical Trials Unit), Drs Victor Turkumude and Ivan Mambule (trial coordinators), Mr. Kenneth Katumba (economist).

Role: Review of study progress, including staff and resource issues; ensure study is administered in a financially responsible manner; report to the Ministry of Health on the study’s progress and achievements, as necessary.

Trial status

Recruitment is expected to begin in November 2019 and continue until the last quarter of 2021.

Current protocol version and date
V2.0, 24th September 2019

Protocol revision chronology
V1.1, 17th May 2019 Original approved protocol
V1.2, 31st May 2019 Amendment 1 (minor, made in response to recommendations of the LSHTM REC)
Added details regarding the Public Liability (negligent harm) and Clinical Trial (non-negligent harm) insurance policies held by LSHTM that apply to this trial
V2.0, 24th September 2019 Amendment 2 (substantial, made in response to recommendations from the TSC, DSMB, TMG and MRC/UVRI REC): Removed ‘mother or neonate enrolled in another MRC/UVRI research project’ as an exclusion criterion; clarified inclusion criterion regarding age at time of screening as ‘≥ 1 hour and < 48 hours’; changed inclusion criterion regarding place of birth to ‘inborn or outborn’; changed inclusion criterion regarding multiple births to ‘singleton, twin, or triplet (triplet if demise or stillbirth of 1 or more fetuses)’; clarified that twins and triplets will be allocated to the same arm, if both are eligible; added study nurse as an additional member of site staff who may obtain informed consent and randomise participants; updated SAE reporting schedule per DSMB; changed secondary outcome regarding feeding to ‘mean time from randomisation to exclusive breastfeeding’; changed other secondary time-related outcomes to ‘mean time from randomisation to...’; clarified secondary outcome regarding readmission to ‘mean frequency of readmission at 28 days’; clarified that length, gestational age assessment, and initial WCI may be delayed to within 48 h of enrolment; changed frequency of surveys on staffing, equipment, and supplies to triannually (every four months); changed timing of process evaluation workshops to 6 months after recruitment begins; changed weight bands for stratification and subgroup analyses to < 1000, 1000–1499, or ≥ 1500 g; added exploratory analyses of association between mortality and time of initiation/continuity of KMC; added detail that KMC wraps will be procured locally per UVRI REC.

Trial sponsor
London School of Hygiene & Tropical Medicine (LSHTM)
Sponsor’s reference: 2019-MUU-234
Contact name: Mrs. Patricia Henley
Address: London School of Hygiene & Tropical Medicine, London, UK
Telephone: + 44 (0)2079272626
Email: rgio@lshtm.ac.uk
The sponsor had no role in trial design, protocol/manuscript preparation, nor the decision to submit the manuscript for publication. The sponsor will play no role in trial conduct, management, or planned analyses, and does not have authority over any of the aforementioned activities. Participants will receive compensation for any harm suffered as a result of the trial, as per the sponsor’s standard indemnity.

Authors’ contributions
MMM and JEL conceived the trial. MMM and JEL prepared the Joint Global Health Trials funding application, with substantial input from CJT, EA, PW, DE and CP. MMM drafted the trial protocol, with substantial input from CJT, EA, PW, DE and CP. MMM drafted the trial protocol, with substantial input from CJT, EA, PW, DE and CP. MMM drafted the protocol, with substantial input from JEL, CJT, PW, RRC, HB, DE and EA. EKK, KK and CP designed the economic evaluation, with input from MMM and JEL. GG designed the women’s wellbeing component, with input from EKK, KK and CP. IM, VT, RRC, KK, MMM and CJT prepared case report forms and SOPs, with input from PW, OH, EKK, HB, DE and EA. MMM and JEL designed the process evaluation, with substantial input from CJT, VT, PW, JS and DE. The study protocol will be implemented by VT, IM, MMM, CJT, RRC and KK, with oversight by JEL, PW, EA, MN, DE, EE and CP. MMM drafted the manuscript. All authors participated in manuscript revision and approval of the final version.

Funding
This trial is funded by the Joint Global Health Trials scheme of the Department of Health and Social Care, the Department for International Development, the Medical Research Council and the Wellcome Trust (#MR/S004971/1, Additional file 5). Additional funding from the Eunice Kennedy
Shriver National Institute of Child Health and Human Development of the National Institutes of Health (#K23HD092611) is supporting Dr. Melissa Medvedev’s work on the trial. The funders played no role in trial design nor the decision to submit the protocol for publication. The funders will not play a role in trial conduct nor in collection, analysis or interpretation of data.

Availability of data and materials
The final trial dataset will be available upon request to the PI or an institutional delegate. We plan to publish the results of the trial and the economic and process evaluations in peer-reviewed journals in an open access format. Manuscripts resulting from the trial will adhere to the Consort Guidelines and to authorship criteria set by the International Committee of Medical Journal Editors. We plan to present study results at international meetings and communicate findings to key audiences, including the WHO and the Ugandan Ministry of Health. Findings will be shared with relevant local stakeholders and participants’ families, adapted for those affected by a death.

Ethics approval and consent to participate
Ethical approval for the study was obtained from the Research Ethics Committees of LSHTM (Additional file 2, reference: 16972), UVRI (Additional file 3, reference: GC/127/19/06/717) and the Uganda National Ethics Committee of UVRI (Additional file 2, reference: 16972), UVRI and LSHTM Uganda Research Unit, PO Box 49, Entebbe, Uganda. 4Department of Neonatal Medicine, University College London, 235 Euston Road, London NW1 2BU, UK. 6Centre of Excellence for Infection and Immunity in Africa (C3IA), University of the Witwatersrand, Johannesburg, South Africa. 8Faculty of Health Sciences, Karolinska Institutet, SE-171 77 Stockholm, Sweden. 8Faculty of Medicine, University of Cape Town, Cape Town, South Africa.

Consent for publication
Written consent for obtaining and publishing the photograph (Fig. 4A) was obtained from the caregiver.

Competing interests
The authors declare that they have no competing interests.

Author details
1Maternal, Adolescent, Reproductive, & Child Health Centre, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 2Department of Paediatrics, University of California San Francisco, 550 16th Street, Box 1224, San Francisco, CA 94158, USA. 3Faculty of Epidemiology and Population Health, London School of Hygiene & Tropical Medicine, Keppel Street, London WC1E 7HT, UK. 4Medical Research Council/UGanda Virus Research Institute and LSHTM Uganda Research Unit, PO Box 49, Entebbe, Uganda. 5Department of Neonatal Medicine, University College London, 235 Euston Road, London NW1 2BU, UK. 6Centre of Excellence for Maternal, Neonborn, and Child Health, School of Public Health, Makerere University, New Mulago Hill Road, Kampala, Uganda. 7Department of Public Health Sciences, Karolinska Institutet, SE-171 77 Stockholm, Sweden. 8Faculty of Public Health and Policy, London School of Hygiene & Tropical Medicine, 15-17 Tavistock Place, London WC1E 7HT, UK. 9Medical Research Council Unit The Gambia at LSHTM, PO Box 273, Fajara, The Gambia.

Received: 13 November 2019 Accepted: 30 December 2019
Published online: 31 January 2020

References
1. UN Inter-agency Group for Child Mortality Estimation, Levels & trends in child mortality: report 2019. New York: UNICEF; 2019. https://www.unicef.org/media/60561/file/UN-IGME-child-mortality-report-2019.pdf. Accessed 14 Oct 2019
2. Oza S, Cousens S, Lawn J. Estimation of daily risk of neonatal death, including the day of birth, in 186 countries in 2013: A vital-registration and modelling-based analysis. Lancet. 2014;384:189–205.
3. Lawn J, Blencowe H, Oza S, You D, Lee A, Waiswa P, et al. Progress, priorities, and potential beyond survival. Lancet. 2014;384:189–205.
4. Blencowe H, Krasevci J, de Onis M, Black R, An X, Stevens G, et al. National, regional, and worldwide estimates of low birthweight in 2015, with trends from 2000: a systematic analysis. Lancet Glob Health. 2019;7:e849–60.
5. Chawanpaiboon S, Vogel J, Moller A, Lumbiganon P, Petzold M, Hogan D, et al. Global, regional, and national estimates of levels of preterm birth in 2014: a systematic review and modelling analysis. Lancet Glob Health. 2017;5:e37–46.
6. Blencowe H, Cousens S, Oestergaard M, Chou D, Moller A, Narwal R, et al. National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: A systematic analysis and implications. Lancet. 2012;379:2162–72.
7. Moxon S, Lawn J, Dickson K, Simen-Kapets A, Gupta G, Deorari A, et al. Inpatient care of small and sick newborns: a multi-country analysis of health system bottlenecks and potential solutions. BMC Pediatr. 2015;15(Suppl 2):S7.
8. Morgan M, Spindler H, Nambuya H, Nakwa N, Namazizi G, Waiswa P, et al. Clinical cascades as a novel way to assess physical readiness of facilities for the care of small and sick newborns in Kenya and Uganda. PLoS One. 2018;13:e0207156.
9. Bhutta Z, Das J, Bahl R, Lawn J, Salam R, Paul V, et al. Can available interventions end preventable deaths in mothers, newborn babies, and stillbirths, and at what cost? Lancet. 2014;383:347–70.
10. World Health Organization. Kangaroo mother care: a practical guide. Geneva: WHO; 2004. http://www.who.int/maternal_child_adolescent/documents/9241590351/en/. Accessed 1 June 2019
11. Conde-Aguado A, Diaz-Rosello J. Kangaroo mother care to reduce morbidity and mortality in low birthweight infants. Cochrane Database Syst Rev. 2016;2:CD007271.
12. Boundy E, Dastjerdi R, Spiegelman D, Waifee W. Kangaroo Mother Care and neonatal outcomes: a meta-analysis. Pediatrics. 2016;137:e20152238.
13. World Health Organization. WHO recommendations on interventions to improve preterm birth outcomes. Geneva WHO, 2015. http://apps.who.int/iris/bitstream/10665/180337/1/9789241508988_eng.pdf. Accessed 12 Apr 2019
14. Morgan M, Nambuya H, Waiswa P, Tann C, Elbourne D, Seely J, et al. Kangaroo Mother Care for clinically unstable neonates: is it feasible at a hospital in Uganda? J Glob Health. 2018;8:010701.
15. Worku B, Kasie A. Kangaroo Mother Care: a randomized controlled trial on effectiveness of early Kangaroo Mother Care for the low birthweight infants in Addis Ababa, Ethiopia. J Trop Pediatr. 2005;51:93–7.
16. English M, Karumbi J, Mina M, Aluvaala J, Gupta A, Zwarenstein M, et al. The need for pragmatic clinical trials in low and middle income settings – taking essential neonatal interventions delivered as part of inpatient care as an illustrative example. BMC Med. 2016;14:5.
17. Chan G, Valsangkar B, Kajepeta S, Boundy E, Wall S, Ave H. What is kangaroo mother care? Systematic review of the literature. J Glob Health. 2016;6:010701.
18. Cattaneo A, Davanzo R, Worku B, Surjono A, Echeverria M, Bedir A, et al. Kangaroo mother care for low birthweight infants?: a randomized controlled trial in different settings. Acta Paediatr. 1998;87:736–85.
19. Le B, Chapek N, Castillo M, Bernal A, Rios J, Trujillo T, et al. Economic evaluation of Kangaroo Mother Care cost utility analysis of results from a randomized controlled trial conducted in Bogotá. J Clin Epidemiol. 2017;86:91–100.
20. Lima G, Quintero-Romero S, Cattaneo A. Feasibility, acceptability and cost of kangaroo mother care in Recife, Brazil. Ann Trop Paediatr. 2000;20:226–6.
21. Broughton E, Gomez L, Sanchez N, Vindell C. The cost-savings of implementing kangaroo mother care in Nicaragua. Rev Panam Salud Publica. 2013;34:176–82.
22. Cong X, Ludington-Hoe S, McCain G, Fu P. Kangaroo care modifies preterm infant heart rate variability in response to heel stick pain: pilot study. Early Hum Dev. 2009;85:561–6.
23. Mitchell A, Yates C, Williams K, Hall R. Effects of daily Kangaroo Mother Care for clinically unstable neonates: adapted for those affected by a death.
24. Acuña-Muga J, Ureta-Velasco N, De La Cruz-Bértolo J, Ballesteros-López R, Sánchez-Martínez R, Miranda-Casabona E, et al. Volume of milk obtained in mothers of VLBW infants. MCN Am J Matern Child Nurs. 2016;6:010701.
25. Parker L, Sullivan S, Krueger C, Kelechi T, Mueller M. Strategies to increase Kangaroo Mother Care for clinically unstable neonates: focused training on Kangaroo Mother Care for the nursing staff at a hospital in Uganda? J Glob Health. 2018;8:010701.
